Related Experiment Videos
Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue
M Colombel1, R Dante, R Bouvier
1Department of Urology, Hospital Edouard Herriot, France.
Prostate Cancer and Prostatic Diseases
|December 24, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Candidates to salvage therapy after external-beam radiotherapy of prostate cancer: Predictors of local recurrence volume and metastasis-free survival.
Diagnostic and interventional imaging·2020
[Focal HIFU vs robot-assisted total prostatectomy: Functionnal and oncologic outcomes at one year].
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2018
[Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy?]
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2018
Variability induced by the MR imager in dynamic contrast-enhanced imaging of the prostate.
Diagnostic and interventional imaging·2018
Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.
Prostate cancer and prostatic diseases·2026
Oncological and functional outcomes of focal irreversible electroporation for localised prostate cancer: a single institution series of 171 cases.
Prostate cancer and prostatic diseases·2026
Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.
Prostate cancer and prostatic diseases·2026
Prostate size and its effect on sexual function following convective water vapor thermal therapy.
Prostate cancer and prostatic diseases·2026
Successful cabazitaxel desensitization after severe taxane hypersensitivity reactions: a brief report.
Prostate cancer and prostatic diseases·2026
Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States.
Prostate cancer and prostatic diseases·2026